Compare Ascendis Pharma A/S (ASND) vs Quantumscape Corp (QS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Quantumscape Corp — how do they compare? Ascendis Pharma A/S trades at $253.76 (market cap $16.78B), while Quantumscape Corp trades at $6.35 (market cap $3.81B). The key difference: Ascendis Pharma A/S is far larger — about 4.4× Quantumscape Corp's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Quantumscape Corp nearer its low. Which is the better fit depends on your goals.
| ASND | QS | |
|---|---|---|
Market Cap | $16.78B | $3.81B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $18.44 |
52-Week Low | $189.74 | $4.89 |
Enterprise Value | $17.15B | $3.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.41, up 2.23% with a bullish technical signal. The company shows strong revenue growth from $364M in 2024 to $720M in 2025, though remains unprofitable with a net loss of $228M. Recent news highlights positive clinical trial results for achondroplasia treatments and inclusion in Russell indexes. Analyst consensus is strongly bullish with 92% buy ratings and a $309.75 price target, representing 21% upside potential.
ASND presents significant growth potential with multiple product launches and expanding rare endocrine franchise, but carries substantial risk due to negative equity, high debt levels, and ongoing losses. The transition to profitability projected for 2026 with $496M net income represents a key inflection point. Investors should weigh the strong analyst optimism against the company's financial leverage and execution risks in drug commercialization.
QuantumScape (QS) trades at $6.075, up 9.86% in the last session, with a bullish technical signal overall despite mixed moving averages and oscillators. The company reported a net loss of $435.05 million in 2025, with negative ROE and ROA, and has no revenue as it develops solid-state battery technology. Recent news highlights partnerships with Volkswagen and Honda, but the stock fell 31% in July 2026 amid commercialization delays.
The outlook remains speculative, with potential upside tied to successful battery commercialization by 2029, but high execution risks and persistent losses warrant caution. Analyst sentiment is neutral to bearish, with 73% hold ratings, reflecting uncertainty over timelines and funding needs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Quantumscape Corp
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
Read more on QS →
